Consulting Analytical Scientist

Waters Corporation reported second quarter 2026 revenue of $1.645 billion, exceeding guidance. Organic revenue grew 7% as reported and 9% in constant currency to $828 million, driven by 8% instrument growth and double-digit chemistry consumables growth in the Analytical Sciences Division. The recently acquired Biosciences and Diagnostic Solutions businesses generated $817 million in revenue, growing 4% on a comparable basis and exceeding guidance by $15 million. Adjusted earnings per share reached $3.05, landing at the high end of guidance. Waters raised its full-year 2026 guidance, now expecting organic constant currency revenue growth of 7% to 9%, acquired business revenue of $3.045 billion, and adjusted EPS of $14.45 to $14.65, reflecting 10-12% growth.

Waters (NYSE:WAT) updates Q3 2026 earnings guidance. August 4, 2026 Key points. * Waters issued Q3 2026 guidance for EPS of $3.95-$4.05 and revenue of $1.7-$1.8 billion, broadly in line with analyst expectations. Full-year 2026 EPS guidance was set at $14.45-$14.65. * Analysts maintain a generally positive view, with Waters carrying a consensus "Moderate Buy" rating and an average price target of $402.47. * Shares rose to $388.17 following the update, while institutional investors hold approximately 94% of the company's stock. * MarketBeat previews top five stocks to own in September. Waters (NYSE:WAT - Get Free Report) issued an update on its third quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.950-4.050 for the period, compared to the consensus earnings per share estimate of 4.010. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion. Waters also updated its FY 2026 guidance to 14.450-14.650 EPS. Analyst ratings changes. A number of equities analysts have recently commented on WAT shares. Bank of America lifted their price objective on Waters from $370.00 to $400.00 and gave the stock a "neutral" rating in a research note on Tuesday, June 2nd. Wells Fargo & Company upped their price objective on shares of Waters from $355.00 to $370.00 and gave the company an "equal weight" rating in a research report on Thursday, May 14th. Robert W. Baird set a $387.00 price objective on shares of Waters in a research note on Wednesday, May 6th. Wall Street Zen lowered shares of Waters from a "buy" rating to a "hold" rating in a research report on Monday, July 20th. Finally, Morgan Stanley increased their price target on shares of Waters from $350.00 to $390.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 9th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Waters currently has an average rating of "Moderate Buy" and a consensus price target of $402.47. Waters price performance. NYSE WAT traded up $13.43 on Tuesday, hitting $388.17. 571,218 shares of the company were exchanged, compared to its average volume of 1,023,551. Waters has a 1-year low of $275.05 and a 1-year high of $414.15. The company has a market cap of $38.11 billion, a P/E ratio of 49.27, a P/E/G ratio of 2.28 and a beta of 1.20. The company has a current ratio of 1.79, a quick ratio of 1.13 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $369.92 and a two-hundred day moving average of $344.99. Discover more Stock Average Calculator Waters (NYSE:WAT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, beating analysts' consensus estimates of $3.01 by $0.04. Waters had a return on equity of 15.60% and a net margin of 11.91%.Waters's quarterly revenue was up 113.3% compared to the same quarter last year. During the same period last year, the business posted $2.95 EPS. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. On average, equities analysts predict that Waters will post 14.51 EPS for the current year. Institutional inflows and outflows. Several hedge funds have recently modified their holdings of the business. Veritas Asset Management LLP increased its position in shares of Waters by 112.3% in the 4th quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier's stock valued at $471,447,000 after buying an additional 656,436 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Waters by 509.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 671,103 shares of the medical instruments supplier's stock worth $254,906,000 after purchasing an additional 561,047 shares during the period. Marshall Wace LLP increased its stake in Waters by 1,611.3% during the 4th quarter. Marshall Wace LLP now owns 581,063 shares of the medical instruments supplier's stock worth $220,705,000 after purchasing an additional 547,109 shares in the last quarter. Invesco Ltd. raised its holdings in Waters by 32.3% during the 3rd quarter. Invesco Ltd. now owns 1,472,419 shares of the medical instruments supplier's stock worth $441,446,000 after buying an additional 359,596 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in Waters in the fourth quarter valued at approximately $70,316,000. Institutional investors own 94.01% of the company's stock. Waters company profile. Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses. Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Waters, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list. While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Waters launches industry's most sensitive and robust clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer. Jul 27, 2026, 08:10 ET * Brings Xevo(TM) TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. * Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volumes, introducing a step-change in analytical performance for complex biological matrices. * Up to six-fold increase in robustness with StepWave(TM) XR Ion Guide vs. Xevo TQ Absolute MS, advancing laboratory productivity and performance consistency. MILFORD, Mass., July 27, 2026 /CNW/ - The Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting - Waters Corporation (NYSE: WAT) today announced the launch of the Xevo TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak(TM) IVD System portfolio of LC-MS/MS Systems with a solution that combines class-leading sensitivity and enhanced robustness for clinical applications. The new system builds on the industry-renowned step-change performance of the Xevo TQ Absolute IVD Mass Spectrometer, which established the benchmark for sensitivity among IVD-compliant tandem quadrupole mass spectrometers.[1] Developed for routine laboratory testing requiring IVD-compliant systems, the Xevo TQ Absolute XR IVD System delivers exceptional trace-level analytical performance in complex biological matrices. With up to five times greater sensitivity than other instruments in its class,[1] the system enables lower limits of detection and reliable quantification of challenging analytes from smaller sample volumes. This enhanced sensitivity is critical for applications requiring accurate measurement at very low concentrations, such as low-level estradiol testing for women's health and hormone-related cancer assessment,[2] and hair toxicology[3] for detecting drugs of abuse and documenting long-term exposure. "Waters' IVD Systems provide clinical diagnostic laboratories with highly precise and flexible solutions that help clinicians make informed decisions when every test matters," said Jianqing Bennett, Senior Vice President, Waters Advanced Diagnostics, Waters Corporation. "With the introduction of the Xevo TQ Absolute XR IVD System, Waters is delivering a new standard of sensitivity and robustness that can significantly reduce downtime and improve laboratory productivity. Waters is uniquely positioned to help clinical laboratories develop reliable methods for complex analytes and expand their testing capabilities to meet growing demand across women's health, cancer assessment, and toxicology applications." Featuring the new StepWave(TM) XR Ion Guide, the Xevo TQ Absolute XR IVD System delivers improved robustness, enabling ion ratio consistency for up to six times longer compared with the Xevo TQ Absolute IVD System.[4] This advancement gives laboratories greater confidence in consistent performance when analyzing complex clinical samples containing phospholipids, salts, and other matrix components. "Having the Xevo TQ Absolute XR IVD Systems in our laboratory is a major advancement for the company," said James Nutt, Head of Laboratory Operations, Cansford Laboratories. "The systems strengthen our analytical reliability, have the potential to greatly expand our substance testing capabilities, and improve operational efficiency. They deliver better signal stability and improved sensitivity, which is especially important when working close to decision cut-offs in complex matrices such as human hair. This gives us greater confidence in our results and provides additional assurance when measuring analytes at very low concentrations." This new MassTrak LC-MS/MS IVD System includes the ACQUITY(TM) UPLC I-Class PLUS System with the Xevo TQ Absolute XR IVD Mass Spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to deliver fast, accurate sample analysis that enhances mass spectrometer performance and simplifies the characterization of complex samples. Together, the integrated system delivers industry-leading sensitivity, enhanced robustness for complex sample matrices, and a user-friendly design that helps maximize laboratory uptime. The MassTrak LC-MS/MS IVD System with the Xevo TQ Absolute XR Mass Spectrometer is available to order now. Additional Resources: * Product Page * Application Note: Utilizing the New Xevo TQ Absolute XR Mass Spectrometer for the LC-MS/MS Analysis of Serum Estrogens for Clinical Research * Application Note: Extraction and Analysis of a Definitive Drug Panel in Hair Samples by UHPLC-MS/MS for Forensic Toxicology Xevo, StepWave, MassTrak, ACQUITY, and Waters are trademarks of Waters Corporation or its affiliates. All other marks are the property of their respective owners. About Waters Corporation: Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about. References: 1. Waters comparison of Xevo TQ Absolute XR IVD vs. existing Waters Xevo TQ-XS IVD and the SCIEX 6500 IVD, which are the next two most sensitive IVD-compliant tandem quadrupole products currently available for commercial sale. 2. Application Note: "Utilizing the New Xevo TQ Absolute XR Mass Spectrometer for the LC-MS/MS Analysis of Serum Estrogens for Clinical Research"; published May 20, 2026. 3. Application Note: "Extraction and Analysis of a Definitive Drug Panel in Hair Samples by UHPLC-MS/MS for Forensic Toxicology"; published June 10, 2025. 4. Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR MS compared to the Xevo TQ Absolute MS; more than 12,000 samples of pesticides in fish feed matrix were analyzed. SOURCE Waters Corporation